Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;9(2):199–216. doi: 10.1111/j.1527-3458.2003.tb00249.x

Valproate: Past, Present, and Future

Cecilie U Johannessen 1,✉, Svein I Johannessen 2
PMCID: PMC6741662  PMID: 12847559

ABSTRACT

Preclinical studies have been carried out during the past four decades to investigate the different mechanisms of action of valproate (VPA). The mechanisms of VPA which seem to be of clinical importance include increased GABAergic activity, reduction in excitatory neurotransmission, and modification of monoamines. These mechanisms are discussed in relation to the various clinical uses of the drug. VPA is widely used as an antiepileptic drug with a broad spectrum of activity. In patients, VPA possesses efficacy in the treatment of various epileptic seizures such as absence, myoclonic, and generalized tonic‐clonic seizures. It is also effective in the treatment of partial seizures with or without secondary generalization and acutely in status epilepticus.

The pharmacokinetic aspects of VPA and the frequent drug interactions between VPA and other drugs are discussed. The available methods for the determination of VPA in body fluids are briefly evaluated.

At present, investigations and clinical trials are carried out and evaluated to explore the new indications for VPA in other conditions such as in psychiatric disorders, migraine and neuropathic pain. Furthermore, the toxicity of VPA, both regarding commonly occurring side effects and potential idiosyncratic reactions are described. Derivatives of VPA with improved efficacy and tolerability are in development.

Keywords: Anticonvulsants, Epilepsy, Valproate

Full Text

The Full Text of this article is available as a PDF (129.0 KB).

References

  • 1. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000;22:62–65. [DOI] [PubMed] [Google Scholar]
  • 2. Albus A, Williamson R. Electrophysical analysis of the action of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia 1998;39:124–139. [DOI] [PubMed] [Google Scholar]
  • 3. Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001;42 (Suppl 1): 46–49. [DOI] [PubMed] [Google Scholar]
  • 4. Anderson GD. Children versus adults: Pharmacokinetic and adverse‐effect differences. Epilepsia 2002;43 (Suppl 3): 53–59. [DOI] [PubMed] [Google Scholar]
  • 5. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: A double‐blind, concentration‐response design clinical trial. Depakote monotherapy for partial seizures study group. Neurology 1997;48:182–188. [DOI] [PubMed] [Google Scholar]
  • 6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:1–41. [DOI] [PubMed] [Google Scholar]
  • 7. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat conference (EILAT V). Epilepsy Res 2001;43:11–58. [DOI] [PubMed] [Google Scholar]
  • 8. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca, E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat conference (Eilat VI). Epilepsy Res 2002;51:31–71. [DOI] [PubMed] [Google Scholar]
  • 9. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: An in vivo microdialysis study. Brain Res 1992;594:138–142. [DOI] [PubMed] [Google Scholar]
  • 10. Biton V, Mirza W, Montouris G, Voung A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172–177. [DOI] [PubMed] [Google Scholar]
  • 11. Blaheta RA, Cinatl J Jr, Anti‐tumor mechanisms of valproate: A novel role of an old drug. Med Res Rev 2002;22:492–511. [DOI] [PubMed] [Google Scholar]
  • 12. Blaheta RA, Nau H, Michaelis M, Cinatl J, Jr. Valproate and valproate analogues: Potent tools to fight against cancer. Curr Med Chem 2002;9:1417–1433. [DOI] [PubMed] [Google Scholar]
  • 13. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28 (Suppl 2): S8–S11. [DOI] [PubMed] [Google Scholar]
  • 14. Bourgeois B. Valproic acid. Clinical efficacy and use in epilepsy In: Levy RH, Mattson RH, Meldrum BS, Perucca E, Eds. Antiepileptic drugs. 5th Edition Philadelphia : Lippincott Williams & Wilkins, 2002;808–817. [Google Scholar]
  • 15. Braathen G, Theorell K, Persson A, Rane A. Valproate in the treatment of absence epilepsy in children: A study of dose‐response relationships. Epilepsia 1988;29:548–552. [DOI] [PubMed] [Google Scholar]
  • 16. Brambilla P, Barale F, Soares JC. Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2001;4:421–446. [DOI] [PubMed] [Google Scholar]
  • 17. Brennan NJW, Sandyk R, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects In: Okuma T, Müller AA, Eds. Anticonvulsants in affective disorders. Amsterdam : Emrich Excerpta Medica, 1994;56–65. [Google Scholar]
  • 18. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: Implications for weight gain. Metabolism 1992;41:666–670. [DOI] [PubMed] [Google Scholar]
  • 19. Calabrese JR, Markowitz P, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid‐cycling bipolar patients. J Clin Psychopharmacol 1992;43:487–490. [DOI] [PubMed] [Google Scholar]
  • 20. Chapman AG. Cerebral energy metabolism and seizures In: Pedley TA, Meldrum BS, Eds. Recent advances in epilepsy. Edinburgh : Churchill‐Livingstone, 1985;19–63. [Google Scholar]
  • 21. Chapman AG, Riley K, Evans MC, Meldrum BS. Acute effects of sodium valproate and γ‐vinyl GABA on regional amino acid metabolism in the rat brain: Incorporation of 2‐[14C]glucose into amino acids. Neurochem Res 1982;7:1089–1109. [DOI] [PubMed] [Google Scholar]
  • 22. Chapman SA, Wacksman GP, Patterson BD. Pancreatitis associated with valproic acid: A review of the literature. Pharmacotherapy 2001;21:1549–1560. [DOI] [PubMed] [Google Scholar]
  • 23. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open‐label, nonrandomized chart study. Clin Ther 2002;24:1576–1584. [DOI] [PubMed] [Google Scholar]
  • 24. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263–272. [DOI] [PubMed] [Google Scholar]
  • 25. Corbo J. The role of anticonvulsants in preventive migraine therapy. Curr Pain Headache 2003;7:63–66. [DOI] [PubMed] [Google Scholar]
  • 26. Cummins TR, Jiang C, Haddad GG. Human neocortical excitability is decreased during anoxia via sodium channel modulation. J Clin Invest 1993;91:608–615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Cutrer FM. Antiepileptic drugs: How they work in headache. Headache 2001;41 (Suppl 1): S3–S10. [DOI] [PubMed] [Google Scholar]
  • 28. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:579–585. [DOI] [PubMed] [Google Scholar]
  • 29. Czuczwar SJ, Frey H‐H, Löscher W. Antagonism of N‐methyl‐D, L‐aspartatic acid‐induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 1985;108:273–280. [DOI] [PubMed] [Google Scholar]
  • 30. Davies R, Peters DH, McTravish D. Valproic acid: A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332–372. [PubMed] [Google Scholar]
  • 31. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pedriatr Neurol 2000;22:361–364. [DOI] [PubMed] [Google Scholar]
  • 32. Dixon JF, Hokin LE. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5–triphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates. Proc Natl Acad Sci USA 1997;94:4757–4760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic hepatic fatalities: A retrospective review. Neurology 1987;37:379–385. [DOI] [PubMed] [Google Scholar]
  • 34. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities II: US experience since 1984. Neurology 1988;33:201–207. [DOI] [PubMed] [Google Scholar]
  • 35. Duncan S. Polycystic ovarian syndrome in women with epilepsy: A review. Epilepsia 2001;42 (Suppl 3): 60–65. [DOI] [PubMed] [Google Scholar]
  • 36. Fariello RG, Varasi M, Smith MC. Valproic acid, mechanisms of action In: Levy RH, Mattson RH, Meldrum BS, Eds. Antiepileptic drugs. 4th Edition New York : Raven Press, 1995;581–588. [Google Scholar]
  • 37. Franceschetti S, Hamon B, Heineman U. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on evoked changes in [Ca2+]o and [K+]o in the hippocampal slice. Brain Res 1986;386:1–11. [DOI] [PubMed] [Google Scholar]
  • 38. Frank EL, Schwarz EL, Juenke J, Annesley TM, Roberts WL. Performance characteristics of four immuno‐assays for antiepileptic drugs on the IMMUNOLITE 2000 automated analyser. Am J Clin Pathol 2002;118:124–131. [DOI] [PubMed] [Google Scholar]
  • 39. Gaillard WD, Zeffiro T, Fazilat S, Decarli C, Theodore WH. Effect of valproate on cerebral metabolism and blood flow: An 18F‐2‐deoxyglucose and 15O water positron emission tomography study. Epilepsia 1996;37:515–21. [DOI] [PubMed] [Google Scholar]
  • 40. Gean PW. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 1994;33:333–336. [DOI] [PubMed] [Google Scholar]
  • 41. Genton P, Bauer J, Duncan S et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001;42:295–304. [DOI] [PubMed] [Google Scholar]
  • 42. Genton P, Gelisse P. Valproic acid. Adverse effects In: Levy RH, Mattson RH, Meldrum BS, Perucca E, Eds. Antiepileptic drugs. 5th Edition Philadelphia : Lippincott Williams & Wilkins, 2002;837–851. [Google Scholar]
  • 43. Ghose K, Niven B. Prophylactic sodium valproate therapy in patients with drug‐resistant migraine. Methods Find Exp Clin Pharmacol 1998;20:353–359. [DOI] [PubMed] [Google Scholar]
  • 44. Godin Y, Heier L, Mark J, Mandel P. Effects of di‐n‐propylacetate, an anticonvulsant compound, on GABA metabolism. J Neurochem 1969;16:869–873. [DOI] [PubMed] [Google Scholar]
  • 45. Gram L, Flachs H, Würtz‐Jørgensen A, Parnas J, Andersen B. Sodium valproate, serum levels and clinical effect in epilepsy: A controlled study. Epilepsia 1979;20:303–312. [DOI] [PubMed] [Google Scholar]
  • 46. Grünschlag CR, Haas HL, Stevens DR. 5‐HT inhibits lateral entorhinal cortical neurons of the rat in vitro by activation of potassium channel‐coupled 5‐HT1A receptors. Brain Res 1997;770:10–17. [DOI] [PubMed] [Google Scholar]
  • 47. Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R. A phase II study to esablish the efficacy and toxicity of sodium valproate in patients with cancer‐related neuropathic pain. J Pain Symptom Manage 2001;21:204–209. [DOI] [PubMed] [Google Scholar]
  • 48. Hassel B, Sonnewald U. Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3–nitropropionic acid in vivo. J Neurochem 1995;65:1–8. [DOI] [PubMed] [Google Scholar]
  • 49. Henriksen O, Johannessen Si. Clinical and pharmacokinetic observations on sodium valproate‐a 5‐year follow‐up study in 100 children with epilepsy. Acta Neurol Scand 1982;65:504–523. [DOI] [PubMed] [Google Scholar]
  • 50. Herzog AG, Schachter SC. Valproate and polycystic ovary syndrome: Final thoughts. Epilepsia 2001;42:311–315. [DOI] [PubMed] [Google Scholar]
  • 51. Hjelm M, de Silva LV, Seakins JW, Oberholzer VG, Rolles CJ. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 1986;292:23–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Honeycutt D, Callahan K, Rutledge L, Wans B. Heterozygotic ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate treatment. Neurology 1992;42:666–668. [DOI] [PubMed] [Google Scholar]
  • 53. Horton RW, Anlezark GM, Sawaya MC, Meldrum BS. Monoamine and GABA metabolism and the anticonvulsant action of di‐n‐propylacetate and ethanolamine‐O‐sulphate. Eur J Pharmacol 1977;41:387–397. [DOI] [PubMed] [Google Scholar]
  • 54. Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol 2001;39:381–392. [DOI] [PubMed] [Google Scholar]
  • 55. Isoherränen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV 1901): A new antiepileptic drug. Epilepsia 2001;42:831–836. [DOI] [PubMed] [Google Scholar]
  • 56. Isoherränen N, White HS, Finnell RH, Woodhead JH, Bennett GD, Bialer M. Anticonvulsant activity and teratogenicity of valrocemide (TV 1901). Epilepsia 2001;42(Suppl 7): 212. [DOI] [PubMed] [Google Scholar]
  • 57. Isojärvi JI, Taubøll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: A response and an alternative view. Epilepsia 2001;42:305–310. [DOI] [PubMed] [Google Scholar]
  • 58. Jaeken J, Caesar P, Corbeel L. Valproate, hyperammonemia and hyperglycinaemia. Lancet 1980;2:260. [DOI] [PubMed] [Google Scholar]
  • 59. Jeavons PM. Non‐dose‐related side effects of valproate. Epilepsia 1984;25 (Suppl 1): S50–S55. [DOI] [PubMed] [Google Scholar]
  • 60. Johannessen CU. Mechanisms of action of valproate: A commentatory. Neurochem Int 2000;37:103–110. [DOI] [PubMed] [Google Scholar]
  • 61. Johannessen CU, Qu H, Sonnewald U, Hassel B, Fonnum F. Estimation of aspartate synthesis in GABAergic neurons in mice by 13C NMR spectroscopy. Neuroreport 2001;12:3729–32. [DOI] [PubMed] [Google Scholar]
  • 62. Johannessen CU, Petersen D, Fonnum F, Hassel B. The acute effect of valproate on cerebral energy metabolism in mice. Epilepsy Res 2002;47:247–56. [DOI] [PubMed] [Google Scholar]
  • 63. Johannessen SI. Preliminary observations on valproic acid kinetics in patients with epilepsy. Arzneimittel-forschung 1977;27:1083–1085. [PubMed] [Google Scholar]
  • 64. Johannessen SI. General principles. Methods of determination of antiepileptic drugs In: Levy RH, Mattson RH, Meldrum BS, Eds. Antiepileptic drugs. 4th Edition New York : Raven Press, 1995;243–70. [Google Scholar]
  • 65. Johannessen SI. Plasma drug concentration monitoring of anticonvulsants. Practical guidelines. CNS Drugs 1997;7:349–65. [Google Scholar]
  • 66. Johannessen SI, Henriksen O. Serum levels of di‐n‐propyl acetate in epileptic patients. Pharm Weekblad 1977;112:287–289. [Google Scholar]
  • 67. Johannessen SI, Henriksen O. Pharmacokinetic observations of sodium valproate in healthy subjects and in patients with epilepsy In: Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, Eds. Antiepileptic therapy: Advances in drug monitoring. New York : Raven Press, 1980;131–140. [Google Scholar]
  • 68. Johannessen SI, Henriksen O, Munthe‐Kaas AW, Salvesen B. Serum concentration profile studies of tablets and suppositories of valproate in healthy subjects and in patients with epilepsy In: Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, Eds. Metabolism of antiepileptic drugs. New York : Raven Press, 1984;61–71. [Google Scholar]
  • 69. Jones TH. Sodium valproate‐induced menstrual disturbances in young women. Hormone Res 1991;35:82–85. [DOI] [PubMed] [Google Scholar]
  • 70. Keck PE, Jr. , McElroy SL, Tugrul KC, Bennett JA. Valproate loading dose in the treatment of acute mania. J Clin Psych 1993;54:305–308. [PubMed] [Google Scholar]
  • 71. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977;21:736–743. [DOI] [PubMed] [Google Scholar]
  • 72. Kusamakar V, Yatham LN, Haslam DR, et al. Treatment of mania, mixed state, and rapid cycling. Can J Psych 1997;42 (Suppl 2): 79S–86S. [PubMed] [Google Scholar]
  • 73. Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia 1991;32:417–422. [DOI] [PubMed] [Google Scholar]
  • 74. Leuchter AF, Cook IA, Uitjdehaage SH, et al. Brain structure and function and the outcomes of treatment for depression. J Clin Psych 1997;58:22–31. [PubMed] [Google Scholar]
  • 75. Lindberger M, Tomson T, Wallstedt L, Stahle L. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: A microdialysis study. Epilepsia 2001;26:256–261. [DOI] [PubMed] [Google Scholar]
  • 76. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 1999;36:453–470. [DOI] [PubMed] [Google Scholar]
  • 77. Luder AS, Parks JK, Frerman F, Parker WD. Inactivation of beef brain á‐ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Am Soc Clin Invest 1990;86:1574–1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharm 1981;30:1364–1366. [DOI] [PubMed] [Google Scholar]
  • 79. Löscher W. Valproate: A reappraisal of its pharmacodynamic properties and mechansisms of action. Prog Neurobiol 1999;58:31–59. [DOI] [PubMed] [Google Scholar]
  • 80. Löscher W. Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669–694. [DOI] [PubMed] [Google Scholar]
  • 81. Löscher W. Valproic acid. Mechanisms of action In: Levy RH, Mattson RH, Meldrum BS, Perucca E, Eds. Antiepileptic drugs. 5th Edition Philadelphia : Lippincott Williams & Wilkins, 2002;767–779. [Google Scholar]
  • 82. Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid. Neurology 1981;31:159. [Google Scholar]
  • 83. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy: A meta‐analysis. Epilepsia 2002;43:505–513. [DOI] [PubMed] [Google Scholar]
  • 84. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 2001;41 (Suppl 1): S18–S24. [DOI] [PubMed] [Google Scholar]
  • 85. Mattson RH, Cramer JA, Collins JF. A comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic‐clonic seizures in adults. N Engl J Med 1992;327:765–771. [DOI] [PubMed] [Google Scholar]
  • 86. Maura G, Carbone R, Guido M, Pestarino M, Raiteri M. 5‐HT2 presynaptic receptors mediate inhibition of glutamate release from cerebellar mossy fibre terminals. Eur J Pharmacol 1991;202:185–190. [DOI] [PubMed] [Google Scholar]
  • 87. Maura G, Marcoli M, Tortarolo M, Androli GC, Raiteri M. Glutamate release in human cerebral cortex and its modulation by 5–hydroxytyramine acting at 5‐HT1D receptors. Br J Pharmacol 1998;123:45–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. McElroy SL, Keck PE, Jr. , Tugrul KC, Bennett JA. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146–149. [DOI] [PubMed] [Google Scholar]
  • 89. McElroy SL, Keck PE, Jr. Experience with valproate in affective disorders In: Modingh K, Robak OH, Vestergaard P, Eds. Anticonvulsants in psychiatry. Petersfield : Wrightson Biomedical Publishing, 1994;57–72. [Google Scholar]
  • 90. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use‐ and voltage‐dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001–1011. [PubMed] [Google Scholar]
  • 91. Meshki‐Baf MH, Subhash MN, Madepalli Lakshamana K, Sridhara Rama Rao BS. Sodium valproate induced alterations inmonoamine levels in different regions of the rat brain. Neurochem Int 1994;1:67–72. [DOI] [PubMed] [Google Scholar]
  • 92. Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M. Properiètès pharmacodynamiques de lìacide n‐dipropylacetique. Therapie 1963;18:435–438. [PubMed] [Google Scholar]
  • 93. Mitsikostas D, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: A randomised, double‐open, clinical trial. Func Neurol 1997;12:267–276. [PubMed] [Google Scholar]
  • 94. Monaco F, Piredda S, Mutani R, Mastropaolo C, Tondi M. The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid. Epilepsia 1982;23:23–26. [DOI] [PubMed] [Google Scholar]
  • 95. Mortensen PB, Koluraa S, Christensen, E. Inhibition of the glycine cleavage system: Hyperglycinemia and hyperglycinuria caused by valproic acid. Epilepsia 1980;21:563–69. [DOI] [PubMed] [Google Scholar]
  • 96. Musshoff U, Madeja M, Düsing R, et al. Valproate affects glutamate but not GABA receptors. Eur J Neurosci 1996;9(Suppl): 205. [Google Scholar]
  • 97. Muzina DJ, El‐Sayegh S, Calabrese JR. Antiepileptic drugs in psychiatry‐focus on randomised controlled trial. Epilepsy Res 2002;50:195–202. [DOI] [PubMed] [Google Scholar]
  • 98. Nakajima M, Yamato S, Shimada K, et al. Assessment of drug concentrations in tears in therapeutic drug monitoring: I. Determination of valproic acid in tears by gas chromatography/mass spectrometry with EC/NCI mode. Ther Drug Monit 2000;22:716–722. [DOI] [PubMed] [Google Scholar]
  • 99. Nobler MS, Sackeim HA, Prophovnik I, et al. Regional cerebral blood flow in mood disorders. III. Treatment and clinical response. Arch Gen Psych 1994;51:884–897. [DOI] [PubMed] [Google Scholar]
  • 100. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: A critical review. Epilepsia 2002;43:1421–1424. [DOI] [PubMed] [Google Scholar]
  • 101. Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 2002;16:695–714. [DOI] [PubMed] [Google Scholar]
  • 102. Petroff OAC, Rothman DL, Behar KL, Hyder F, Mattson RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 1999;8:120–127. [DOI] [PubMed] [Google Scholar]
  • 103. Price DJ. Intravenous valproate: Experience in neurosurgery In: Chadwick D, Ed. Fourth international symposium on sodium valproate and epilepsy. London : Royal Society of Medicine Services, 1989;197–203. [Google Scholar]
  • 104. Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998;30:41–48. [DOI] [PubMed] [Google Scholar]
  • 105. Richens A, Davidson DLW, Cartlidge, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psych 1994;57:682–687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000;55 (Suppl 1): S41–46. [PubMed] [Google Scholar]
  • 107. Rowan AJ. Valproate In: Engel J, Jr., Pedley TA, Eds. Epilepsy: A comprehensive textbook. Philadelphia : Lippincott‐Raven Publishers, 1997;1599–1607. [Google Scholar]
  • 108. Rubin E, Sackeim HA, Prohovnik I, Moeller JR, Schnur DB, Mukherjee S. Regional cerebral blood flow in mood disorders: IV. Comparison of mania and depression. Psych Res 1995;61:1–10. [DOI] [PubMed] [Google Scholar]
  • 109. Sato S, Kitagawa S, Nakajima M, Shimada K, Honda A, Miyazaki H. Assessment of tear concentrations on therapeutic drug monitoring. II. Pharmacokinetic analysis of valproic acid in guinea pig serum, cerebro‐spinal fluid, and tears. Pharm Res 2001;18:500–509. [DOI] [PubMed] [Google Scholar]
  • 110. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;14:445–449. [DOI] [PubMed] [Google Scholar]
  • 111. Silberstein SD. Valproic acid. Clinical efficacy and use in other neurological disorders In: Levy RH, Mattson RH, Meldrum BS, Perucca E, Eds. Antiepileptic drugs. 5th Edition Philadelphia : Lippincott Williams & Wilkins, 2002;818–827. [Google Scholar]
  • 112. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: An open‐term study. Long‐term safety of Depakote in headache prophylaxis study group. Headache 1999;39:633–643. [DOI] [PubMed] [Google Scholar]
  • 113. Stoll AL, Banov M, Kolbrener M. Neurologic factors predict a favorable valproate response in schizo‐affective disorders. J Clin Psychopharmacol 1994;14:311–313. [PubMed] [Google Scholar]
  • 114. Swann AC. Valproic acid. Clinical efficacy and use in psychiatric disorders In: Levy RH, Mattson RH, Meldrum BS, Perucca E, Eds. Antiepileptic drugs. 5th Edition Philadelphia : Lippincott Williams & Wilkins, 2002;828–836. [Google Scholar]
  • 115. Thomas AB, Mathews GC, Ferrendelli JA. Mechanisms of action of antiepileptic drugs In: Wyllie E, Ed. The treatment of epilepsy: Principles and practice. 2nd Edition Baltimore : Williams & Wilkins, 1996;700–711. [Google Scholar]
  • 116. Tomson T, Gram L, Sillanpää M, Johannessen SI. Recommendations for the management and care of pregnant women with epilepsy In: Tomson T, Gram L, Sillanpää M, Johannessen SI, Eds. Epilepsy and pregnancy. Petersfield : Wrightson Biomedical Publishing, 1997;201–208. [Google Scholar]
  • 117. Trimble MR, Thompson PJ. Sodium valproate and cognitive function. Epilepsia 1984;25 (Suppl 1): S60–S64. [DOI] [PubMed] [Google Scholar]
  • 118. Van der Laan JW, De Boer T, Bruinvels J. Di‐n‐propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA‐transaminase. J Neurochem 1979;32:1769–1780. [DOI] [PubMed] [Google Scholar]
  • 119. Vayer P, Cash CD, Maitre M. Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral γ‐hydroxybutyrate system Trends Pharmacol Sci 1988;9:127–129. [DOI] [PubMed] [Google Scholar]
  • 120. Verotti A, Basciani F, Moressi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230–232. [DOI] [PubMed] [Google Scholar]
  • 121. Vining EPG. Cognitive dysfunction associated with antiepileptic drug therapy. Epilepsia 1987;28 (Suppl 2): S18–S22. [DOI] [PubMed] [Google Scholar]
  • 122. Williams CA, Tiefenbach S, McReynolds JW. Valproic acid‐induced hyperammonemia in mentally retarded adults. Neurology 1984;34:550–553. [DOI] [PubMed] [Google Scholar]
  • 123. Yamamoto R, Yanagita T, Kobayashi H, Yokoo, H , Wada A. Up‐regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: Activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J Neurochem 1997;68:1655–1662. [DOI] [PubMed] [Google Scholar]
  • 124. Zaccara G, Paganini M, Campostrini R, et al. Effect of associated antiepileptic treatment on valproate‐induced hyperammonemia. Ther Drug Monit 1985;7:185–190. [DOI] [PubMed] [Google Scholar]
  • 125. Zeise ML, Kasparow S, Zieglgänsberger W. Valproate supresses N‐methyl‐D‐aspartate‐evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991;544:345–348. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES